Related Experiment Videos
The Heartpod implantable heart failure therapy system.
1Alfred Hospital, Prahran, Vic., Australia. twalton@bigpond.net.au
Heart, Lung & Circulation
|December 15, 2005
Summary
Congestive heart failure patients can now precisely manage their treatment. An implantable device measures left atrial pressure, allowing real-time self-titration for improved outcomes.
Area of Science:
- Cardiology
- Biomedical Engineering
- Medical Devices
Background:
- Congestive heart failure (CHF) remains a significant health challenge with high mortality rates.
- Current drug therapies and cardiac resynchronization devices have limitations in treating CHF effectively.
- Diastolic dysfunction in CHF patients often leads to suboptimal treatment outcomes.
Purpose of the Study:
- To introduce the Heartpod device for direct measurement of left atrial pressure in CHF patients.
- To enable patients to actively participate in managing their CHF treatment.
- To explore a novel approach for precise, real-time titration of CHF therapy.
Main Methods:
- Development of an implantable device (Heartpod) by Savacor Company.
- Real-time monitoring of intra-cardiac pressure (left atrial pressure).
- Data transmission to a patient-held handheld device for review and titration.
Main Results:
- The Heartpod device allows for direct and continuous measurement of left atrial pressure.
- Patients can access their pressure data in real time.
- This enables precise, individualized titration of CHF treatment by the patient.
Conclusions:
- The Heartpod device offers a new paradigm for managing congestive heart failure.
- Empowering patients with real-time data facilitates more accurate self-management of their condition.
- This technology has the potential to improve treatment efficacy and patient outcomes in CHF.